WOCKHARDT BIO AG
GenericsWOCKHARDT BIO AG is a generic drug manufacturer focused on Infectious Disease, Metabolic, Neurology. Key products include ZAYNICH.
WOCKHARDT BIO AG at a Glance
- Fast trial execution (5 months median completion)
WOCKHARDT BIO AG's Key Drugs
WOCKHARDT BIO AG's core commercial portfolio centers on ZAYNICH, spanning Infectious Disease and Metabolic — its most strategically important drugs approved in the last 15 years.
WOCKHARDT BIO AG's Recent FDA Approvals
WOCKHARDT BIO AG secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
WOCKHARDT BIO AG's Therapeutic Areas
WOCKHARDT BIO AG's approved drugs and pipeline span 5 therapeutic areas, led by Infectious Disease and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
WOCKHARDT BIO AG's Top Competitors
WOCKHARDT BIO AG's closest competitors by therapeutic-area and drug-target overlap include Merck, Sanofi, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
WOCKHARDT BIO AG Pipeline Snapshot
WOCKHARDT BIO AG has 13 active clinical programs from ClinicalTrials.gov — 4 Phase 3, 1 Phase 2 and 8 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ZAYNICH leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/4 completed
- • Speed: 5 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1984-08-16
- Latest
- 2026-05-29
- Applications
- 28
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges